Subtopic Deep Dive
Uric Acid and Cardiovascular Risk Factors
Research Guide
What is Uric Acid and Cardiovascular Risk Factors?
Uric acid and cardiovascular risk factors research investigates the causal links between hyperuricemia, endothelial dysfunction, hypertension, oxidative stress from xanthine oxidase, and atherosclerotic cardiovascular disease.
Hyperuricemia associates with hypertension, vascular disease, renal disease, and cardiovascular events (Johnson et al., 2003, 1351 citations). Experimental studies show uric acid induces endothelial dysfunction via oxidative stress (Khosla et al., 2005, 1194 citations). Urate-lowering therapies like allopurinol lower blood pressure in hypertensive adolescents (Feig et al., 2008, 914 citations). Over 50 papers from provided lists span epidemiology to mechanisms.
Why It Matters
Elevated uric acid acts as a modifiable risk factor for cardiovascular disease, prompting risk stratification in hypertension guidelines. Johnson et al. (2003) link hyperuricemia to hypertension and vascular damage, influencing trials like Feig et al. (2008) where allopurinol reduced adolescent blood pressure by 6 mmHg systolic. Khosla et al. (2005) demonstrate uric acid impairs endothelial nitric oxide, promoting atherosclerosis. Berry and Hare (2003) highlight xanthine oxidoreductase inhibition as a therapeutic target, with NLRP3 inflammasome activation (Shao et al., 2015) exacerbating vascular inflammation in hyperuricemia patients.
Key Research Challenges
Causality vs Association
Distinguishing causal roles of uric acid from confounding factors like obesity remains difficult. Johnson et al. (2003) review epidemiology but note experimental validation gaps. Randomized trials like Feig et al. (2008) show blood pressure benefits, yet larger CVD outcome studies are needed.
Mechanistic Pathways
Oxidative stress via xanthine oxidase and NLRP3 inflammasome activation requires clearer endothelial models. Khosla et al. (2005) prove uric acid-induced dysfunction; Berry and Hare (2003) detail XOR mechanisms. Integrating inflammation data from Kang et al. (2005) poses integration challenges.
Therapy Translation
Translating allopurinol benefits from adolescents to adults with CVD endpoints is unresolved. Feig et al. (2008) report hypertension efficacy, but long-term atherosclerotic outcomes lack data. Urate-lowering impacts on NLRP3 (Shao et al., 2015) need clinical verification.
Essential Papers
Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?
Richard J. Johnson, Duk‐Hee Kang, Daniel I. Feig et al. · 2003 · Hypertension · 1.4K citations
Hyperuricemia is associated with hypertension, vascular disease, renal disease, and cardiovascular events. In this report, we review the epidemiologic evidence and potential mechanisms for this ass...
Regulation of uric acid metabolism and excretion
Jessica Maiuolo, Francesca Oppedisano, Santo Gratteri et al. · 2015 · International Journal of Cardiology · 1.3K citations
Purines perform many important functions in the cell, being the formation of the monomeric precursors of nucleic acids DNA and RNA the most relevant one. Purines which also contribute to modulate e...
Hyperuricemia induces endothelial dysfunction
Uday M. Khosla, Sergey Zharikov, Jennifer Finch et al. · 2005 · Kidney International · 1.2K citations
Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications
Cristine E. Berry, Joshua M. Hare · 2003 · The Journal of Physiology · 916 citations
There is substantial evidence that oxidative stress participates in the pathophysiology of cardiovascular disease. Biochemical, molecular and pharmacological studies further implicate xanthine oxid...
Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension
Daniel I. Feig, Beth Soletsky, Richard J. Johnson · 2008 · JAMA · 914 citations
clinicaltrials.gov Identifier: NCT00288184.
Uric Acid–Induced C-Reactive Protein Expression
Duk‐Hee Kang, Sung-Kwang Park, In‐Kyu Lee et al. · 2005 · Journal of the American Society of Nephrology · 877 citations
Recent experimental and human studies have shown that hyperuricemia is associated with hypertension, systemic inflammation, and cardiovascular disease mediated by endothelial dysfunction and pathol...
Uric acid transport and disease
Alexander So, Bernard Thorens · 2010 · Journal of Clinical Investigation · 835 citations
Uric acid is the metabolic end product of purine metabolism in humans. It has antioxidant properties that may be protective but can also be pro-oxidant, depending on its chemical microenvironment. ...
Reading Guide
Foundational Papers
Start with Johnson et al. (2003) for epidemiologic overview (1351 citations), then Khosla et al. (2005) for endothelial mechanisms (1194 citations), and Feig et al. (2008) for clinical trial evidence (914 citations).
Recent Advances
Study Paik et al. (2021, 758 citations) on NLRP3 regulation and Lanaspa et al. (2012, 678 citations) on uric acid oxidative stress for updated pathways.
Core Methods
Core techniques include rat models of hyperuricemia-induced hypertension (Johnson et al., 2003), endothelial cell assays for nitric oxide (Khosla et al., 2005), randomized allopurinol trials (Feig et al., 2008), and XOR inhibition studies (Berry and Hare, 2003).
How PapersFlow Helps You Research Uric Acid and Cardiovascular Risk Factors
Discover & Search
Research Agent uses searchPapers and citationGraph to map Johnson et al. (2003) central hub (1351 citations) linking to Khosla et al. (2005) and Feig et al. (2008); exaSearch uncovers mechanistic papers like Berry and Hare (2003) on xanthine oxidase.
Analyze & Verify
Analysis Agent applies readPaperContent to extract uric acid levels and BP correlations from Feig et al. (2008), then runPythonAnalysis with pandas for meta-analysis of hypertension effects across Johnson et al. (2003) datasets; verifyResponse via CoVe and GRADE grades causal evidence as moderate due to trial limitations.
Synthesize & Write
Synthesis Agent detects gaps in adult CVD trials beyond adolescent data (Feig et al., 2008), flags NLRP3 contradictions between Shao et al. (2015) and vascular papers; Writing Agent uses latexEditText, latexSyncCitations for Johnson et al. (2003), and latexCompile for review manuscripts with exportMermaid diagrams of uric acid pathways.
Use Cases
"Meta-analyze uric acid levels vs blood pressure from allopurinol trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas regression on Feig et al. 2008 + similar trials) → statistical output with p-values and effect sizes.
"Draft LaTeX review on xanthine oxidase in hyperuricemia CVD"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Berry and Hare 2003, Khosla et al. 2005) → latexCompile → formatted PDF review.
"Find code for simulating uric acid endothelial models"
Research Agent → paperExtractUrls (Johnson et al. 2003) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for oxidative stress simulations.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ uric acid CVD papers starting with citationGraph on Johnson et al. (2003), outputs structured report with GRADE-scored evidence. DeepScan applies 7-step analysis to Feig et al. (2008) trial, verifying BP reductions via CoVe checkpoints. Theorizer generates hypotheses on NLRP3 inhibition (Shao et al., 2015) for vascular protection from Khosla et al. (2005) mechanisms.
Frequently Asked Questions
What defines uric acid's role in cardiovascular risk?
Hyperuricemia links to hypertension, endothelial dysfunction, and CVD events via oxidative stress (Johnson et al., 2003; Khosla et al., 2005).
What are key methods studied?
Experimental models show uric acid reduces endothelial nitric oxide; clinical trials test allopurinol for BP lowering (Khosla et al., 2005; Feig et al., 2008).
What are foundational papers?
Johnson et al. (2003, 1351 citations) reviews epidemiology; Khosla et al. (2005, 1194 citations) proves endothelial effects; Feig et al. (2008, 914 citations) demonstrates therapy.
What open problems exist?
Causal proof in adults, long-term CVD outcomes, and NLRP3 integration lack large RCTs beyond adolescent data (Feig et al., 2008; Shao et al., 2015).
Research Gout, Hyperuricemia, Uric Acid with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Uric Acid and Cardiovascular Risk Factors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Gout, Hyperuricemia, Uric Acid Research Guide